04May 2014
Springer

MrOs Sweden. Osteoporos Int 2014;25:1831-1836

Serum adiponectin is a risk factor for fracture. Nevertheless, the predictive value attenuates with time so that its use for the risk assessment in the long term is questionable. This study underlines the importance of testing the long-term stability of potential risk factors that might be used in fracture risk assessment..

Autor: H. Johansson, A. Odén, M. K. Karlsson, E. McCloskey, J. A. Kanis, C. Ohlsson, D. Mellström
04May 2014
jama

JAMA Intern Med. 2014 May 5. doi: 10.1001/jamainternmed.2014.162. [Epub ahead of print]

The clinical utility of medication monitoring has been a controversial issue in osteoporosis management. In the 1998 and 20012 coverage rules commonly called the “Bone Mass Measurement Act,” the Centers for Medicare & Medicaid Services (CMS) outlined provisions for bone mineral density (BMD) and bone turnover marker measurements for Medicare beneficiaries. The CMS covers BMD testing for 5 indications and bone turnover marker testing for 3 indications, including monitoring of US Food and Drug Administration–approved osteoporosis drug therapy. The CMS authorizes BMD measurements if at least 23 months have passed since the last measurement, or more frequently “when medically necessary.”1(p34324) The CMS also summarized appropriate use of bone turnover markers, assuming documentation of medical necessity: “because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.

Autor: Gourlay ML, Ensrud KE.
04May 2014
jama

JAMA Intern Med. 2014 May 5. doi: 10.1001/jamainternmed.2014.1232. [Epub ahead of print]

Among postmenopausal women who discontinue alendronate therapy after 4 to 5 years, age and hip BMD at discontinuation predict clinical fractures during the subsequent 5 years. Follow-up measurements of DXA 1 year after discontinuation and of BAP or NTX 1 to 2 years after discontinuation are not associated with fracture risk and cannot be recommended.

Autor: Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM.
04May 2014
Springer

JAMA. 2014 May 28;311(20):2083-91. doi: 10.1001/jama.2014.5052.

Vitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D insufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma.

Autor: Castro M, King TS, Kunselman SJ, Cact.ana MD, Denlinger L, Holguin F, Kazani SD, Moore WC, Moy J.etc
04May 2014

Bone 2014; 62:22-28

Notch1 and Notch2 inactivation increased porosity and reduced thickness of cortical bone. These effects were modest and more evident in 3 and 6 month old female than in male mice of the same age. In conclusion, Notch1 and Notch2 expression in osteoblast precursors regulates cancellous bone volume and microarchitecture.

Autor: Zanotti S, Canali E.
04May 2014
bone logo

Bone. 2015 May 24;79:37-42. doi: 10.1016/j.bone.2015.05.022. [Epub ahead of print]

The maintenance of bone homeostasis is largely dependent upon cellular communication between osteoclasts and osteoblasts. Microvesicles (MVs) have received a good deal of attention and are increasingly considered as mediators of intercellular communication due to their capacity to merge with and transfer a repertoire of bioactive molecular content (cargo) to recipient cells, triggering a variety of biologic responses. Here, we demonstrated that MVs shed from osteoblasts contain RANKL protein and can transfer it to osteoclast precursors through receptor ligand (RANKL-RANK), leading to stimulation of RANKL-RANK signaling to facilitate osteoclast formation. Such MV-mediated intercellular communication between osteoblasts and osteoclasts may represent a novel mechanism of bone modeling and remodeling. It may be worthwhile to further explore MVs as tools to modify the biological responses of bone cells or develop an alternative drug to treat bone diseases.

Autor: Deng L, Wang Y, Peng Y, Wu Y, Ding Y, Jiang Y, Shen Z, Fu Q.
04Abr 2014
Springer

Calcif Tissue Int. 2014 Jun;94(6):597-607. doi: 10.1007/s00223-014-9855-6. Epub 2014 Apr 6.

These results provide further evidence that PPI use may increase fracture risk in the elderly and highlight the need for clinicians to periodically reassess elderly patients’ individualized needs for ongoing PPI therapy, while weighing potential risks and benefits

Autor: Ding J, Heller DA, Ahern FM, Brown TV
04Abr 2014
bone logo

Bone 61 (2014) 138–148.

This review examines recent developments in the understanding of why the elderly hip becomes fragile. This growing understanding is suggesting novel testable approaches for reducing risk of hip fracture that might translate into control of the growing worldwide impact of hip fractures on our ageing populations.

Autor: Reeve J, Loveridge N.
05Mar 2014
endocrine society

Mol Endocrinol. 2014 Jul;28(7):1150-65

We conclude that osteocytogenesis is accompanied by changes in gene expression that may be driven by both genetic and epigenetic components. These changes are likely responsible for the osteocyte phenotype and may contribute to reduced sensitivity to 1,25(OH)(2)D(3).

Autor: St John HC, Bishop KA, Meyer MB, Benkusky NA, Leng N, Kendziorski C, Bonewald LF, Pike JW.